GlassScriptPhysician profile
Herbert H Rosengarten
NPI 1912947029
$4,140.25
in general payments reported to CMS, 2019-2025
31 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $1,192 · 2021: $854 · 2022: $398 · 2023: $280 · 2024: $578 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $702.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $447.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $434.63 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $396.88 | 2019-2024 | Livalo |
| Merck Sharp & Dohme LLC | $313.97 | 2019-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.82 | 2019-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $269.28 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $222.86 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $190.92 | 2019-2022 | |
| Amgen INC. | $179.31 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $154.49 | 2021-2023 | Ubrelvy |
| Allergan, INC. | $129.57 | 2020 | |
| Exact Sciences Corporation | $52.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $51.97 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $46.26 | 2023-2025 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $37.34 | 2020 | |
| Amryt Pharma Holdings LTD | $25.08 | 2022-2023 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.06 | 2025 | Voquezna |
| Abbott Laboratories | $17.63 | 2024 | Freestyle Libre 3 |
| Biogen, INC. | $15.34 | 2022 | |
| Linus Health, INC. | $14.80 | 2023 | |
| Intra-Sana Laboratories | $14.66 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Acadia Pharmaceuticals INC | $14.46 | 2025 | Daybue |
| Almatica Pharma LLC | $14.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.69 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.69 | 2022 | |
| Sanofi Pasteur INC. | $13.16 | 2020 | |
| Dexcom, INC. | $12.06 | 2022 | |
| Sobi, INC | $11.34 | 2021 | |
| Athena Bioscience, LLC | $9.82 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Rosengarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.